Botulinum toxin in ENT in detail
Reading File
Finding Sources
Finding Sources
Searching PubMed
"botulinum toxin" AND "otolaryngology"
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Loading Image
I now have comprehensive information from Cummings Otolaryngology, KJ Lee's Otolaryngology, and other references. Let me compile the detailed answer.
Botulinum Toxin in ENT — A Comprehensive Review
Mechanism of Action
Botulinum toxin (BTX) is produced by Clostridium botulinum, with eight antigenically distinct serotypes (A–H). Type A (BoNT-A) has the widest pharmaceutical use; Type B is also clinically available. BTX prevents the presynaptic release of acetylcholine at cholinergic nerve terminals by cleaving SNAP-25 (synaptosome-associated protein 25 kDa), which is essential for vesicle-membrane fusion. This produces:
- Chemodenervation of skeletal muscle → flaccid paralysis (motor applications)
- Chemical parasympathectomy of secretory glands → reduced secretion (autonomic applications)
Chemical denervation occurs 2–3 days post-injection and lasts 3–9 months depending on the preparation used. Axonal sprouting and re-innervation eventually restore function.
ENT Applications
1. Laryngeal Dystonia (Spasmodic Dysphonia) ⭐ Primary ENT Use
Spasmodic dysphonia (SD) is an idiopathic focal laryngeal dystonia classified by Cummings as a hyperfunctional disorder of the larynx. It has two main forms:
| Type | Muscles | Voice Characteristics |
|---|---|---|
| Adductor SD (most common) | Thyroarytenoid (TA), lateral cricoarytenoid (LCA) | Strained, strangled, effortful; voiced-syllable breaks |
| Abductor SD | Posterior cricoarytenoid (PCA) | Breathy phonation breaks on voiceless consonants |
| Mixed SD | Both | Combined features |
BTX is the gold standard treatment for SD. The mechanism exploits the toxin's ability to weaken the hyperkinetic muscle groups selectively.
Adductor SD — Injection Technique
- Target: Thyroarytenoid muscle bilaterally
- Approach: Transcutaneous, percricothyroid membrane, EMG-guided (hollow EMG needle confirms intramuscular placement)
- Dose: Starting dose 1.25–2.5 units (Botox) per side bilaterally; adjusted based on response
- Patient is asked to phonate /i/ to confirm TA activity on EMG
- Effect onset: 3–7 days; duration: 3–4 months on average
Abductor SD — Injection Technique
- Target: Posterior cricoarytenoid muscle (the only abductor of the vocal fold)
- Approach: Posterior lateral approach (thyroid cartilage rotated, needle placed at posterior lateral cricoid) — see Fig. 57.2 from Cummings below
- Dose: ~3.75–5 units unilaterally (one side at a time to avoid bilateral PCA weakness and airway compromise)
- EMG confirmation: patient performs a "sniff" maneuver to recruit PCA motor units
Fig. 57.2 — Lateral approach to the PCA muscle. The thyroid cartilage is rotated laterally; a 27-gauge needle is inserted into the posterior lateral aspect of the cricoid. The EMG shows volitional "sniff" maneuvers confirming PCA muscle placement. (Cummings Otolaryngology)
Outcomes
- 90%+ patients experience significant voice improvement
- Side effects: Transient breathiness, hypophonia, mild dysphagia (from local diffusion) — typically resolve within days to weeks
- Treatment is not curative; repeated injections required every 3–4 months
2. Essential Vocal / Laryngeal Tremor
Vocal tremor accompanies essential tremor in ~30% of cases and may also present in isolation. It manifests as a tremulous, quavering voice with visible laryngeal oscillation.
BTX protocol (Cummings):
- Horizontal glottic tremor (bilateral thyroarytenoid involvement): bilateral TA injections, 1 unit per side (starting dose)
- Vertical laryngopharyngeal tremor (strap muscle involvement): bilateral strap muscle injections, 2.5–5 units per side
- If both components present: injections are alternated 3–8 weeks apart to avoid dysphagia and aspiration
BTX reduces the amplitude of tremor and improves fluency, though it does not eliminate the tremor entirely. Propranolol and primidone remain systemic options; deep brain stimulation is an alternative for refractory cases.
3. Sialorrhea (Drooling)
Indication: Chronic sialorrhea in neurologically impaired patients (cerebral palsy, ALS, Parkinson disease, post-stroke), pediatric neuromuscular disorders, and post-parotidectomy states.
Mechanism: BTX blocks parasympathetic cholinergic transmission at salivary gland acini → reduces salivary output.
Glands injected:
- Parotid glands (bilateral)
- Submandibular glands (bilateral)
- All four glands may be injected in severe cases
Injection techniques:
- Anatomic landmark palpation
- Ultrasound-guided (preferred for accuracy; reduces risk of diffusion into adjacent neck muscles)
- EMG guidance
Ultrasound-guided BTX injection into parotid/submandibular glands for sialorrhea — office-based, under local anesthesia. (Cummings Otolaryngology)
Duration: 3–9 months depending on product. BoNT-B also has evidence for this indication (longer duration than BoNT-A in glandular applications).
Adverse effects:
- Xerostomia
- Dysphagia / aspiration pneumonia (toxin diffusion into neck muscles)
- Reduced salivary pH → increased dental caries (children require special dental care)
- Chronic use causes measurable gland atrophy on ultrasound, without significant histological change
- Non-responders (~10%) regardless of dose
Stepwise approach: Rehabilitation (positioning, oral motor therapy) → anticholinergics → BTX injection → surgical options (duct ligation, submandibular gland excision)
4. Facial Synkinesis (Post-Facial Paralysis)
After severe facial nerve injury (Bell's palsy, acoustic neuroma surgery, parotidectomy), aberrant re-innervation causes synkinesis — involuntary facial muscle co-contraction.
BTX injection sites in facial synkinesis (KJ Lee's Otolaryngology):
| Synkinesis Type | Target Muscle | Goal |
|---|---|---|
| Ocular synkinesis (eye closure with other movements) | Affected orbicularis oculi | Reduces involuntary lid closure; improves visual field |
| Paralyzed brow droop | Contralateral forehead muscles | Improves dynamic symmetry |
| Mentalis synkinesis (chin dimpling) | Mentalis muscle | Smooths chin |
| Lower lip asymmetry | Contralateral depressor labii inferioris (DLI) | Balances lower lip |
| Platysmal synkinesis | Platysmal bands | Reduces downward oral commissure pull |
| Bogorad syndrome (crocodile tears / epiphora) | Lacrimal gland | Reduces excessive tearing |
From Cummings: In eyelid synkinesis, doses of 40 units into the orbicularis oculi give the best reduction while avoiding ptosis (Chua et al.).
5. Frey Syndrome (Gustatory Sweating)
Pathophysiology: After parotidectomy (or other parotid/submandibular/cervical sympathetic trauma), aberrant reinnervation of sweat glands by regenerating parasympathetic secretomotor fibers causes facial flushing and sweating during mastication. True incidence after parotidectomy: 35–60% (up to 96% subclinical on Minor starch-iodine testing).
Diagnosis: Minor starch-iodine test — iodine painted on face, starch powder dusted, patient chews a sialagogue (lemon wedge); blue-black spots confirm gustatory sweating.
Management:
- Antiperspirant application
- Topical glycopyrrolate 1% roll-on
- Intracutaneous BTX-A injection — effective in severe cases where above measures fail
- Tympanic neurectomy (surgical)
6. Cricopharyngeal Dysfunction / Upper Esophageal Sphincter Spasm
The cricopharyngeus muscle (upper esophageal sphincter, UES) can fail to relax appropriately during swallowing in:
- Post-stroke dysphagia
- Parkinson disease
- ALS / motor neuron disease
- Zenker's diverticulum (associated)
- After total laryngectomy (pharyngoesophageal [PE] segment hypertonicity) — causing failure of tracheoesophageal prosthesis speech
BTX injection:
- Identifies hypertonic PE/UES segment with videofluoroscopy (modified barium swallow) first
- Injected under EMG guidance using a hollow EMG needle into the cricopharyngeal / constrictor pharyngeal muscle
- Dose: 100 units (Botox/onabotulinumtoxinA) or 400 units Dysport for PE segment hypertonicity
- Single injection may produce improvement lasting up to 12 months (post-stroke UES spasm)
- In laryngectomy patients: once fluent TE voice is achieved with BTX, the effect is often long-lasting — possibly due to biofeedback reinforcement; surgical myotomy is rarely needed afterward
7. Non-Allergic (Vasomotor) Rhinitis
BTX exploits its anticholinergic effects on secretory nasal mucosa.
- Injected intranasally into the head of the inferior and middle turbinates
- Reduces rhinorrhea safely with minimal side effects
- Duration: up to 12 weeks (temporary)
- Does not alleviate non-rhinorrhea symptoms (nasal obstruction, sneezing)
- A bridge to more definitive procedures (posterior nasal neurectomy, vidian neurectomy)
8. Hemifacial Spasm
Hemifacial spasm involves painless, irregular involuntary unilateral facial contractions, usually from vascular compression of CN VII at the brainstem.
- BTX is a first-line treatment (alternative to microvascular decompression surgery)
- Injected into the affected hemifacial musculature
- Provides relief for 3–4 months; repeated injections required
- Microvascular decompression (MVD) is curative but reserved for refractory or young patients
9. Post-Laryngectomy PE Segment / Tracheoesophageal Speech
In total laryngectomy patients using tracheoesophageal (TE) voice prostheses, PE segment hypertonicity is the most common cause of failure to achieve fluent prosthetic speech.
- Chemodenervation with BTX type A is the preferred first treatment (before surgical myotomy)
- Dose: 100 MU Botox (or 400 MU Dysport) into constrictor pharyngeal / cricopharyngeus muscle group under EMG guidance
- Diagnostic lidocaine injection first can confirm hypertonicity and predict response
10. Other/Emerging ENT Applications
| Application | Details |
|---|---|
| Stuttering | Experimental; BTX to laryngeal and articulatory muscles to reduce the increased muscle tension; evidence limited |
| Laryngeal myoclonus | Palatal myoclonus with laryngeal involvement may respond to BTX |
| Spastic dysarthria | BTX to hyperactive laryngeal/pharyngeal muscles in pseudobulbar palsy |
| Hyperhidrosis of head/neck | Intradermal injection in hyperhidrosis of scalp or cervicofacial region |
Commercial Preparations and Dosing Considerations
| Product | Type | Equivalence Notes |
|---|---|---|
| Botox (onabotulinumtoxinA) | Type A | Reference standard |
| Dysport (abobotulinumtoxinA) | Type A | ~3–4× higher unit dose needed |
| Xeomin (incobotulinumtoxinA) | Type A | ~1:1 with Botox |
| Myobloc/NeuroBloc (rimabotulinumtoxinB) | Type B | Longer duration for glandular applications; more painful injection |
Preparations are not interchangeable unit-for-unit because of differing manufacturing processes and molecular structures.
Adverse Effects (General ENT)
| Effect | Mechanism | Management |
|---|---|---|
| Transient breathiness/hypophonia | Intended TA weakening (SD); diffusion | Self-limiting; dose reduction next cycle |
| Dysphagia | Diffusion to pharyngeal muscles | Usually transient; soft diet, observation |
| Aspiration pneumonia | Severe dysphagia + diffusion | Rare; most dangerous complication |
| Ptosis (ocular injections) | Levator palpebrae diffusion | Avoid injection too close to orbital rim |
| Xerostomia | Over-reduction of salivary flow | Dose adjustment |
| Dental caries (sialorrhea in children) | Reduced salivary pH + volume | Dental surveillance mandatory |
| Antibody formation | Repeated high doses → reduced efficacy | Use lowest effective dose, maximize injection intervals |
Summary Table: ENT Applications of BTX
| Application | Target | Route | Dose (Botox units) | Duration |
|---|---|---|---|---|
| Adductor SD | Thyroarytenoid (bilateral) | Transcricothyroid EMG-guided | 1.25–2.5 U/side | 3–4 months |
| Abductor SD | Posterior cricoarytenoid (unilateral) | Posterior lateral, EMG-guided | 3.75–5 U/side | 3–4 months |
| Vocal tremor (horizontal) | Thyroarytenoid (bilateral) | EMG-guided | 1 U/side | 3–4 months |
| Vocal tremor (vertical) | Strap muscles (bilateral) | EMG-guided | 2.5–5 U/side | 3–4 months |
| Sialorrhea | Parotid + submandibular glands | US-guided / palpation | Variable (product-dependent) | 3–9 months |
| Facial synkinesis | Multiple facial muscles | Transcutaneous | 40 U orbicularis (synkinesis) | 3–4 months |
| Frey syndrome | Intradermal facial skin | Intradermal | Variable | 3–6 months |
| Cricopharyngeal spasm / PE hypertonicity | Cricopharyngeus / constrictor | EMG-guided transcervical | 100 U Botox | Up to 12 months |
| Non-allergic rhinitis | Inferior/middle turbinate head | Intranasal | — | Up to 12 weeks |
| Hemifacial spasm | Hemifacial musculature | Transcutaneous | Variable | 3–4 months |
Key Teaching Points:
- BTX is the gold standard for adductor and abductor spasmodic dysphonia — repeated injections ~every 3 months
- EMG guidance is essential for laryngeal and cricopharyngeal injections
- Ultrasound guidance is preferred for salivary gland injections
- Facial synkinesis BTX is applied to the affected side (motor) or contralateral side (for symmetry) depending on the specific problem
- Dental surveillance is mandatory in children receiving salivary gland BTX for sialorrhea
- Commercial preparations are not dose-equivalent — Dysport requires ~4× the Botox dose
— Cummings Otolaryngology Head and Neck Surgery (6th ed.), pp. 1063–1154 (Laryngeal Neurology), pp. 1487–1491 (Sialorrhea), pp. 1509 (PE segment), pp. 679 (Facial Paralysis/Synkinesis), pp. 843 (Rhinitis); KJ Lee's Essential Otolaryngology (11th ed.), p. 430 (Chemodenervation)
Generate a quick reference PDF on BTX injection techniques in ENT
Reading File
Running Command
Running Command
Writing File
Running Command
PDF generated successfully. Here it is:
📄
BTX ENT Quick Reference
PDF Document · PDF
What's inside (3 pages, A4):
| Section | Content |
|---|---|
| Cover + Mechanism | Serotypes, SNAP-25 mechanism, onset/duration, commercial preparations table |
| 1. Laryngeal | Adductor SD, Abductor SD (with bilateral PCA warning), Vocal tremor, Cricopharyngeal/PE segment — each with target, approach, EMG guidance, dose, duration |
| 2. Salivary Gland | Sialorrhea (US-guided technique, adverse effects table), Frey syndrome |
| 3. Facial Nerve / Head & Neck | Post-paralysis synkinesis (6 subtypes with specific targets), Hemifacial spasm |
| 4. Nasal | Non-allergic rhinitis — turbinate injection |
| Master Reference Table | All 12 ENT applications on one row-per-row table |
| 5. Adverse Effects | Full table + general cautions box including FDA black box warning |
| References | Cummings, KJ Lee, and recent PubMed citations |
This is a shared conversation. Sign in to Orris to start your own chat.